RxDoctor Payments Data

Genna Barnett

Family · Chattanooga, TNNPI 1063736551

Payments from drug & device makers

$424in general payments, 2019–2025

Across 22 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$184
  • Abbott$123
  • Heartflow, Inc.$31
  • Alnylam Pharmaceuticals Inc.$27
  • Pfizer$17
  • E.r. Squibb & Sons, L.L.C.$14
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$424 in reported general payments places this provider in the 45th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$124,489
Medicare patients
937
Services billed
1,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$89,542
EntrestoSacubitril/Valsartan14$20,079
XareltoRivaroxaban18$19,077
Repatha SureclickEvolocumab24$14,831
Ranolazine ErRanolazine20$3,655
Metoprolol Succinate90$1,759
Ezetimibe35$1,452
Valsartan29$1,294
Bumetanide23$1,110
Potassium Chloride78$1,063
Losartan Potassium77$964
Atorvastatin Calcium52$915
Rosuvastatin Calcium56$811
Torsemide43$742
Isosorbide Mononitrate ErIsosorbide Mononitrate35$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$89,54282 claims
NovartisEntresto$184$20,07914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →